{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:10:10Z","timestamp":1784549410119,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2026.111006","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:44:19Z","timestamp":1770975859000},"page":"111006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-8094","authenticated-orcid":false,"given":"Amr A.","family":"Elsawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Laymon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Sobh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab A.","family":"Nour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mosbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.111006_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111006_bib0002","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)-a summary of the 2024 Guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111006_bib0003","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111006_bib0004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11912-021-01091-1","article-title":"Approaches to non-muscle-invasive bladder cancer","volume":"23","author":"Slovacek","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111006_bib0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 Classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111006_bib0006","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111006_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111006_bib0008","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euf.2021.03.016","article-title":"Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111006_bib0009","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bju.16371","article-title":"Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer","volume":"134","author":"Laukhtina","year":"2024","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111006_bib0010","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X","article-title":"TNM classification of malignant tumors. A comparison between the new (1987) and the old editions","volume":"61","author":"Sobin","year":"1988","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111006_bib0011","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111006_bib0012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bju.12666","article-title":"Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non-muscle-invasive bladder cancer. A step forward or back?","volume":"115","author":"Pellucchi","year":"2015","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111006_bib0013","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","article-title":"Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer","volume":"66","author":"Blazeby","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111006_bib0014","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111006_bib0015","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Gu\u00e9rin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111006_bib0016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bju.14915","article-title":"Update on the guideline of guidelines: non-muscle-invasive bladder cancer","volume":"125","author":"Taylor","year":"2020","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111006_bib0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/cancers16101843","article-title":"Treatment modalities for non-muscle invasive bladder cancer: an updated review","volume":"16","author":"McNall","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111006_bib0018","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111006_bib0019","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111006_bib0020","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111006_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111006_bib0022","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.euf.2018.09.009","article-title":"Managing toxicity of intravesical therapy","volume":"4","author":"Mathes","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111006_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.09.012","article-title":"Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study","volume":"33","author":"Schmidt","year":"2015","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111006_bib0024","first-page":"9480","article-title":"Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer","volume":"25","author":"Siracusano","year":"2018","journal-title":"Can J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111006_bib0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Gu\u00e9rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero","year":"2013","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.urolonc.2026.111006_bib0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/ijerph191710825","article-title":"Impact of effective intravesical therapies on quality of life in patients with non-muscle invasive bladder cancer: a systematic review","volume":"19","author":"Yuen","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111006_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers17071135","article-title":"From bench to bladder: the rise in immune checkpoint inhibition in the treatment of non-muscle invasive bladder cancer","volume":"17","author":"Burns","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:52:05Z","timestamp":1784548325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078143926000177"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111006"}}